{"cluster": 37, "subcluster": 15, "abstract_summ": "Since coronavirus disease 2019 (COVID-19) outbreak, neurologic manifestations have been increasingly reported including encephalopathy;however, the underlying patho-physiology remains mostly unclear [1] Neurotropism of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been suspected [2], though neuropathological studies did not show specific brain changes [3] Besides the SARS-CoV-2 infection, a dysregulated immune response resulting in a massive release of proin-flammatory cytokines is involved in pathogenesis of severe COVID-19 manifestations and multi-organ failure [4] This systemic hyperinflammatory state may be involved in neu-rologic impairment, as well We report a case of COVID-19-related encephalopathy, questioning temporal relations between infection, cytokine storm, and neurologic involvement A 77-year-old female, with no history of neurological disease , presented with impaired consciousness after 18-days history of SARS-CoV-2 infection and acute respiratory distress requiring invasive mechanical ventilation (Fig 1) Patient was placed on hydroxychloroquine, levofloxacin, and piperacillin/tazobactam Despite a remarkable respiratory improvement, at time of first neurologic evaluation, patient presented awake but mutacic, without any goal-directed behavior No meningeal irritations or focal signs were found Stimulus-induced myo-clonus and positive primitive reflexes (blinking, left grasp) were observed Electroencephalogram (EEG) recording showed a generalized slowing activity, prevalent in frontal regions A magnetic resonance imaging (MRI) displayed diffuse white-matter lesions consistent with chronic small vessel disease without contrast enhancement (Fig 2) Cerebrospinal fluid (CSF) analysis detected normal white blood cell counts and mild increase of the blood-brain barrier permeability (CSF protein = 56 mg/dl, reference range &lt; 50;CSF/serum albumin ratio = 15,6, reference range &lt; 7,4) CSF reverse transcription-PCR (RT-PCR) for SARS-CoV-2 was negative Additional CSF studies, including oli-goclonal bands, neurotropic virus, bacterial cultures, and autoimmune encephalitis antibody panel, were all negative Cytokines levels were tested both in CSF and blood documenting a significant increase of interleukin-6 (IL-6) (55 1 and 9 1 pg/ml respectively, reference range &lt; 5,9) and inter-leukin-8 (IL-8) (106 and 2721 pg/ml, respectively, reference range &lt; 70) (Fig 1) 18 F-fluorodeoxyglucose-positron emission tomography (18 F-FDG-PET/CT) scan showed a spread frontal lobe hypo-metabolism (Fig 2) She was treated with intravenous methylprednisolone 60 mg for 10 daysSince coronavirus disease 2019 (COVID-19) outbreak, neurologic manifestations have been increasingly reported including encephalopathy;however, the underlying patho-physiology remains mostly unclear [1] Neurotropism of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been suspected [2], though neuropathological studies did not show specific brain changes [3] Besides the SARS-CoV-2 infection, a dysregulated immune response resulting in a massive release of proin-flammatory cytokines is involved in pathogenesis of severe COVID-19 manifestations and multi-organ failure [4] This systemic hyperinflammatory state may be involved in neu-rologic impairment, as well We report a case of COVID-19-related encephalopathy, questioning temporal relations between infection, cytokine storm, and neurologic involvement A 77-year-old female, with no history of neurological disease , presented with impaired consciousness after 18-days history of SARS-CoV-2 infection and acute respiratory distress requiring invasive mechanical ventilation (Fig 1) Patient was placed on hydroxychloroquine, levofloxacin, and piperacillin/tazobactam Despite a remarkable respiratory improvement, at time of first neurologic evaluation, patient presented awake but mutacic, without any goal-directed behavior No meningeal irritations or focal signs were found Stimulus-induced myo-clonus and positive primitive reflexes (blinking, left grasp) were observed Electroencephalogram (EEG) recording showed a generalized slowing activity, prevalent in frontal regions A magnetic resonance imaging (MRI) displayed diffuse white-matter lesions consistent with chronic small vessel disease without contrast enhancement (Fig 2) Cerebrospinal fluid (CSF) analysis detected normal white blood cell counts and mild increase of the blood-brain barrier permeability (CSF protein = 56 mg/dl, reference range &lt; 50;CSF/serum albumin ratio = 15,6, reference range &lt; 7,4) CSF reverse transcription-PCR (RT-PCR) for SARS-CoV-2 was negative Additional CSF studies, including oli-goclonal bands, neurotropic virus, bacterial cultures, and autoimmune encephalitis antibody panel, were all negative Cytokines levels were tested both in CSF and blood documenting a significant increase of interleukin-6 (IL-6) (55 1 and 9 1 pg/ml respectively, reference range &lt; 5,9) and inter-leukin-8 (IL-8) (106 and 2721 pg/ml, respectively, reference range &lt; 70) (Fig 1) 18 F-fluorodeoxyglucose-positron emission tomography (18 F-FDG-PET/CT) scan showed a spread frontal lobe hypo-metabolism (Fig 2) She was treated with intravenous methylprednisolone 60 mg for 10 daysSince coronavirus disease 2019 (COVID-19) outbreak, neurologic manifestations have been increasingly reported including encephalopathy;however, the underlying patho-physiology remains mostly unclear [1] Neurotropism of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been suspected [2], though neuropathological studies did not show specific brain changes [3] Besides the SARS-CoV-2 infection, a dysregulated immune response resulting in a massive release of proin-flammatory cytokines is involved in pathogenesis of severe COVID-19 manifestations and multi-organ failure [4] This systemic hyperinflammatory state may be involved in neu-rologic impairment, as well We report a case of COVID-19-related encephalopathy, questioning temporal relations between infection, cytokine storm, and neurologic involvement A 77-year-old female, with no history of neurological disease , presented with impaired consciousness after 18-days history of SARS-CoV-2 infection and acute respiratory distress requiring invasive mechanical ventilation (Fig 1) Patient was placed on hydroxychloroquine, levofloxacin, and piperacillin/tazobactam Despite a remarkable respiratory improvement, at time of first neurologic evaluation, patient presented awake but mutacic, without any goal-directed behavior No meningeal irritations or focal signs were found Stimulus-induced myo-clonus and positive primitive reflexes (blinking, left grasp) were observed Electroencephalogram (EEG) recording showed a generalized slowing activity, prevalent in frontal regions A magnetic resonance imaging (MRI) displayed diffuse white-matter lesions consistent with chronic small vessel disease without contrast enhancement (Fig 2) Cerebrospinal fluid (CSF) analysis detected normal white blood cell counts and mild increase of the blood-brain barrier permeability (CSF protein = 56 mg/dl, reference range &lt; 50;CSF/serum albumin ratio = 15,6, reference range &lt; 7,4) CSF reverse transcription-PCR (RT-PCR) for SARS-CoV-2 was negative Additional CSF studies, including oli-goclonal bands, neurotropic virus, bacterial cultures, and autoimmune encephalitis antibody panel, were all negative Cytokines levels were tested both in CSF and blood documenting a significant increase of interleukin-6 (IL-6) (55 1 and 9 1 pg/ml respectively, reference range &lt; 5,9) and inter-leukin-8 (IL-8) (106 and 2721 pg/ml, respectively, reference range &lt; 70) (Fig 1) 18 F-fluorodeoxyglucose-positron emission tomography (18 F-FDG-PET/CT) scan showed a spread frontal lobe hypo-metabolism (Fig 2) She was treated with intravenous methylprednisolone 60 mg for 10 daysSince coronavirus disease 2019 (COVID-19) outbreak, neurologic manifestations have been increasingly reported including encephalopathy;however, the underlying patho-physiology remains mostly unclear [1] Neurotropism of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been suspected [2], though neuropathological studies did not show specific brain changes [3] Besides the SARS-CoV-2 infection, a dysregulated immune response resulting in a massive release of proin-flammatory cytokines is involved in pathogenesis of severe COVID-19 manifestations and multi-organ failure [4] This systemic hyperinflammatory state may be involved in neu-rologic impairment, as well We report a case of COVID-19-related encephalopathy, questioning temporal relations between infection, cytokine storm, and neurologic involvement A 77-year-old female, with no history of neurological disease , presented with impaired consciousness after 18-days history of SARS-CoV-2 infection and acute respiratory distress requiring invasive mechanical ventilation (Fig 1) Patient was placed on hydroxychloroquine, levofloxacin, and piperacillin/tazobactam Despite a remarkable respiratory improvement, at time of first neurologic evaluation, patient presented awake but mutacic, without any goal-directed behavior No meningeal irritations or focal signs were found Stimulus-induced myo-clonus and positive primitive reflexes (blinking, left grasp) were observed Electroencephalogram (EEG) recording showed a generalized slowing activity, prevalent in frontal regions A magnetic resonance imaging (MRI) displayed diffuse white-matter lesions consistent with chronic small vessel disease without contrast enhancement (Fig 2) Cerebrospinal fluid (CSF) analysis detected normal white blood cell counts and mild increase of the blood-brain barrier permeability (CSF protein = 56 mg/dl, reference range &lt; 50;CSF/serum albumin ratio = 15,6, reference range &lt; 7,4) CSF reverse transcription-PCR (RT-PCR) for SARS-CoV-2 was negative Additional CSF studies, including oli-goclonal bands, neurotropic virus, bacterial cultures, and autoimmune encephalitis antibody panel, were all negative Cytokines levels were tested both in CSF and blood documenting a significant increase of interleukin-6 (IL-6) (55 1 and 9 1 pg/ml respectively, reference range &lt; 5,9) and inter-leukin-8 (IL-8) (106 and 2721 pg/ml, respectively, reference range &lt; 70) (Fig 1) 18 F-fluorodeoxyglucose-positron emission tomography (18 F-FDG-PET/CT) scan showed a spread frontal lobe hypo-metabolism (Fig 2) She was treated with intravenous methylprednisolone 60 mg for 10 days", "title_summ": "Older people and COVID-19 updates by medical postgraduate colleges in UK and IrelandFrontal encephalopathy related to hyperinflammation in COVID-19Collateral damage of COVID-19-lockdown in Germany: decline of NSTE-ACS admissionsControl of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients", "title_abstract_phrases": "Older people and COVID-19 updates by medical postgraduate colleges in UK and IrelandSince coronavirus disease 2019 (COVID-19) outbreak, neurologic manifestations have been increasingly reported including encephalopathy;however, the underlying patho-physiology remains mostly unclear [1] Neurotropism of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been suspected [2], though neuropathological studies did not show specific brain changes [3] Besides the SARS-CoV-2 infection, a dysregulated immune response resulting in a massive release of proin-flammatory cytokines is involved in pathogenesis of severe COVID-19 manifestations and multi-organ failure [4] This systemic hyperinflammatory state may be involved in neu-rologic impairment, as well We report a case of COVID-19-related encephalopathy, questioning temporal relations between infection, cytokine storm, and neurologic involvement A 77-year-old female, with no history of neurological disease , presented with impaired consciousness after 18-days history of SARS-CoV-2 infection and acute respiratory distress requiring invasive mechanical ventilation (Fig 1) Patient was placed on hydroxychloroquine, levofloxacin, and piperacillin/tazobactam Despite a remarkable respiratory improvement, at time of first neurologic evaluation, patient presented awake but mutacic, without any goal-directed behavior No meningeal irritations or focal signs were found Stimulus-induced myo-clonus and positive primitive reflexes (blinking, left grasp) were observed Electroencephalogram (EEG) recording showed a generalized slowing activity, prevalent in frontal regions A magnetic resonance imaging (MRI) displayed diffuse white-matter lesions consistent with chronic small vessel disease without contrast enhancement (Fig 2) Cerebrospinal fluid (CSF) analysis detected normal white blood cell counts and mild increase of the blood-brain barrier permeability (CSF protein = 56 mg/dl, reference range &lt; 50;CSF/serum albumin ratio = 15,6, reference range &lt; 7,4) CSF reverse transcription-PCR (RT-PCR) for SARS-CoV-2 was negative Additional CSF studies, including oli-goclonal bands, neurotropic virus, bacterial cultures, and autoimmune encephalitis antibody panel, were all negative Cytokines levels were tested both in CSF and blood documenting a significant increase of interleukin-6 (IL-6) (55 1 and 9 1 pg/ml respectively, reference range &lt; 5,9) and inter-leukin-8 (IL-8) (106 and 2721 pg/ml, respectively, reference range &lt; 70) (Fig 1) 18 F-fluorodeoxyglucose-positron emission tomography (18 F-FDG-PET/CT) scan showed a spread frontal lobe hypo-metabolism (Fig 2) She was treated with intravenous methylprednisolone 60 mg for 10 daysFrontal encephalopathy related to hyperinflammation in COVID-19Since coronavirus disease 2019 (COVID-19) outbreak, neurologic manifestations have been increasingly reported including encephalopathy;however, the underlying patho-physiology remains mostly unclear [1] Neurotropism of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been suspected [2], though neuropathological studies did not show specific brain changes [3] Besides the SARS-CoV-2 infection, a dysregulated immune response resulting in a massive release of proin-flammatory cytokines is involved in pathogenesis of severe COVID-19 manifestations and multi-organ failure [4] This systemic hyperinflammatory state may be involved in neu-rologic impairment, as well We report a case of COVID-19-related encephalopathy, questioning temporal relations between infection, cytokine storm, and neurologic involvement A 77-year-old female, with no history of neurological disease , presented with impaired consciousness after 18-days history of SARS-CoV-2 infection and acute respiratory distress requiring invasive mechanical ventilation (Fig 1) Patient was placed on hydroxychloroquine, levofloxacin, and piperacillin/tazobactam Despite a remarkable respiratory improvement, at time of first neurologic evaluation, patient presented awake but mutacic, without any goal-directed behavior No meningeal irritations or focal signs were found Stimulus-induced myo-clonus and positive primitive reflexes (blinking, left grasp) were observed Electroencephalogram (EEG) recording showed a generalized slowing activity, prevalent in frontal regions A magnetic resonance imaging (MRI) displayed diffuse white-matter lesions consistent with chronic small vessel disease without contrast enhancement (Fig 2) Cerebrospinal fluid (CSF) analysis detected normal white blood cell counts and mild increase of the blood-brain barrier permeability (CSF protein = 56 mg/dl, reference range &lt; 50;CSF/serum albumin ratio = 15,6, reference range &lt; 7,4) CSF reverse transcription-PCR (RT-PCR) for SARS-CoV-2 was negative Additional CSF studies, including oli-goclonal bands, neurotropic virus, bacterial cultures, and autoimmune encephalitis antibody panel, were all negative Cytokines levels were tested both in CSF and blood documenting a significant increase of interleukin-6 (IL-6) (55 1 and 9 1 pg/ml respectively, reference range &lt; 5,9) and inter-leukin-8 (IL-8) (106 and 2721 pg/ml, respectively, reference range &lt; 70) (Fig 1) 18 F-fluorodeoxyglucose-positron emission tomography (18 F-FDG-PET/CT) scan showed a spread frontal lobe hypo-metabolism (Fig 2) She was treated with intravenous methylprednisolone 60 mg for 10 daysCollateral damage of COVID-19-lockdown in Germany: decline of NSTE-ACS admissionsSince coronavirus disease 2019 (COVID-19) outbreak, neurologic manifestations have been increasingly reported including encephalopathy;however, the underlying patho-physiology remains mostly unclear [1] Neurotropism of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been suspected [2], though neuropathological studies did not show specific brain changes [3] Besides the SARS-CoV-2 infection, a dysregulated immune response resulting in a massive release of proin-flammatory cytokines is involved in pathogenesis of severe COVID-19 manifestations and multi-organ failure [4] This systemic hyperinflammatory state may be involved in neu-rologic impairment, as well We report a case of COVID-19-related encephalopathy, questioning temporal relations between infection, cytokine storm, and neurologic involvement A 77-year-old female, with no history of neurological disease , presented with impaired consciousness after 18-days history of SARS-CoV-2 infection and acute respiratory distress requiring invasive mechanical ventilation (Fig 1) Patient was placed on hydroxychloroquine, levofloxacin, and piperacillin/tazobactam Despite a remarkable respiratory improvement, at time of first neurologic evaluation, patient presented awake but mutacic, without any goal-directed behavior No meningeal irritations or focal signs were found Stimulus-induced myo-clonus and positive primitive reflexes (blinking, left grasp) were observed Electroencephalogram (EEG) recording showed a generalized slowing activity, prevalent in frontal regions A magnetic resonance imaging (MRI) displayed diffuse white-matter lesions consistent with chronic small vessel disease without contrast enhancement (Fig 2) Cerebrospinal fluid (CSF) analysis detected normal white blood cell counts and mild increase of the blood-brain barrier permeability (CSF protein = 56 mg/dl, reference range &lt; 50;CSF/serum albumin ratio = 15,6, reference range &lt; 7,4) CSF reverse transcription-PCR (RT-PCR) for SARS-CoV-2 was negative Additional CSF studies, including oli-goclonal bands, neurotropic virus, bacterial cultures, and autoimmune encephalitis antibody panel, were all negative Cytokines levels were tested both in CSF and blood documenting a significant increase of interleukin-6 (IL-6) (55 1 and 9 1 pg/ml respectively, reference range &lt; 5,9) and inter-leukin-8 (IL-8) (106 and 2721 pg/ml, respectively, reference range &lt; 70) (Fig 1) 18 F-fluorodeoxyglucose-positron emission tomography (18 F-FDG-PET/CT) scan showed a spread frontal lobe hypo-metabolism (Fig 2) She was treated with intravenous methylprednisolone 60 mg for 10 daysControl of SARS-CoV-2 infection in rituximab-treated neuroimmunological patientsSince coronavirus disease 2019 (COVID-19) outbreak, neurologic manifestations have been increasingly reported including encephalopathy;however, the underlying patho-physiology remains mostly unclear [1] Neurotropism of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been suspected [2], though neuropathological studies did not show specific brain changes [3] Besides the SARS-CoV-2 infection, a dysregulated immune response resulting in a massive release of proin-flammatory cytokines is involved in pathogenesis of severe COVID-19 manifestations and multi-organ failure [4] This systemic hyperinflammatory state may be involved in neu-rologic impairment, as well We report a case of COVID-19-related encephalopathy, questioning temporal relations between infection, cytokine storm, and neurologic involvement A 77-year-old female, with no history of neurological disease , presented with impaired consciousness after 18-days history of SARS-CoV-2 infection and acute respiratory distress requiring invasive mechanical ventilation (Fig 1) Patient was placed on hydroxychloroquine, levofloxacin, and piperacillin/tazobactam Despite a remarkable respiratory improvement, at time of first neurologic evaluation, patient presented awake but mutacic, without any goal-directed behavior No meningeal irritations or focal signs were found Stimulus-induced myo-clonus and positive primitive reflexes (blinking, left grasp) were observed Electroencephalogram (EEG) recording showed a generalized slowing activity, prevalent in frontal regions A magnetic resonance imaging (MRI) displayed diffuse white-matter lesions consistent with chronic small vessel disease without contrast enhancement (Fig 2) Cerebrospinal fluid (CSF) analysis detected normal white blood cell counts and mild increase of the blood-brain barrier permeability (CSF protein = 56 mg/dl, reference range &lt; 50;CSF/serum albumin ratio = 15,6, reference range &lt; 7,4) CSF reverse transcription-PCR (RT-PCR) for SARS-CoV-2 was negative Additional CSF studies, including oli-goclonal bands, neurotropic virus, bacterial cultures, and autoimmune encephalitis antibody panel, were all negative Cytokines levels were tested both in CSF and blood documenting a significant increase of interleukin-6 (IL-6) (55 1 and 9 1 pg/ml respectively, reference range &lt; 5,9) and inter-leukin-8 (IL-8) (106 and 2721 pg/ml, respectively, reference range &lt; 70) (Fig 1) 18 F-fluorodeoxyglucose-positron emission tomography (18 F-FDG-PET/CT) scan showed a spread frontal lobe hypo-metabolism (Fig 2) She was treated with intravenous methylprednisolone 60 mg for 10 days"}